Inhibiting the nerve cell receptor TRPV1 led to the dual effect of reducing both pain perception and depressive-like behaviors in a mouse model of fibromyalgia, a preliminary study showed. The study, “Involvement of TRPV1 and the efficacy of α-spinasterol on experimental fibromyalgia symptoms in mice,” was published in the journal Neurochemistry International. Fibromyalgia is characterized by widespread chronic pain. A large proportion of patients also deal with debilitating comorbidities — having two chronic diseases or conditions at the same time — such as moderate-to-severe depression and anxiety. Conversely, people with depression report an increased perception of pain and are more likely to develop chronic pain, the researchers said. As these conditions often occur together, "it is highly relevant to identify a compound with a dual-action that could treat both pain and depression symptoms," the investigators said.